PHO-COG-CROOP-ADVL1312; A Phase 1/2 Study of AZD1775 (MK-1775) in Combination With Oral Irinotecan in Children Adolescents and Young Adults With Relapsed or Refractory Solid Tumors
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: Supratentorial Promitive Neuroectodermal Tumor | Medulloblastoma | Neuroblastoma
Age: Between 1 - 21 Years
Gender: Male or Female
In order to be eligible to take part in this trial, patients must meet the following criteria:
- Patients must have had histologic verification of malignancy at original diagnosis or relapse except in patients with intrinsic brain stem tumors, optic pathway gliomas, or patients with pineal tumors and elevations of cerebrospinal fluid (CSF) or serum tumor markers including alpha-fetoprotein or beta-human chorionic gonadotropin (HCG)
- Patient's current disease state must be one for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life
For a full list of participation criteria, please visit ClinicalTrials.gov.
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required